Neurophet Supplies 'Neurophet AQUA' and 'Neurophet AQUA AD Plus' to Elevate Clinic in the U.S., Expanding Its Presence in the U.S. Brain Disorders Market
Provides solutions for analyzing brain atrophy and white matter hyperintensities, as well as monitoring side effects associated with Alzheimer's disease treatments Secures a key reference site at a U.S. medical institution specializing in...
Neurophet Supplies 'Neurophet AQUA' to Raffles Medical in Singapore
Providing Neurophet AQUA capable of analyzing brain atrophy and white matter degeneration… Securing meaningful clinical reference SEOUL, South Korea, July 2, 2026 /PRNewswire/ -- Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial...